



US008518987B2

(12) **United States Patent**  
**Vermeersch et al.**

(10) **Patent No.:** US 8,518,987 B2  
(45) **Date of Patent:** Aug. 27, 2013

(54) **PSEUDOPOLYMORPHIC FORMS OF A HIV PROTEASE INHIBITOR**

(75) Inventors: **Hans Wim Pieter Vermeersch**, Ghent (BE); **Daniel Joseph Christiaan Thone**, Beerse (BE); **Luc Donne Marie-Louise Janssens**, Malle (BE); **Piet Tom Bert Paul Wigerinck**, Terhagen (BE)

(73) Assignee: **Janssen R&D Ireland**, Little Island, Co. Cork (IE)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 276 days.

(21) Appl. No.: **12/536,807**

(22) Filed: **Aug. 6, 2009**

(65) **Prior Publication Data**

US 2010/0204316 A1 Aug. 12, 2010

**Related U.S. Application Data**

(62) Division of application No. 10/514,352, filed as application No. PCT/EP03/50176 on May 16, 2003, now Pat. No. 7,700,645.

(30) **Foreign Application Priority Data**

May 16, 2002 (EP) ..... 02076929

(51) **Int. Cl.**  
*A61K 31/353* (2006.01)

(52) **U.S. Cl.**  
USPC ..... **514/456**; 549/396

(58) **Field of Classification Search**  
USPC ..... 514/456; 549/396  
See application file for complete search history.

(56) **References Cited**

## U.S. PATENT DOCUMENTS

5,413,999 A	5/1995	Vacca et al.
6,071,916 A	6/2000	Askin et al.
6,096,779 A	8/2000	Chikaraishi et al.
6,248,775 B1	6/2001	Vazquez et al.
6,281,367 B1	8/2001	Al-Farhan et al.
6,287,693 B1	9/2001	Savoir et al.
7,700,645 B2	4/2010	Vermeersch et al.
2013/0029945 A1*	1/2013	Phull et al. ..... 514/158

## FOREIGN PATENT DOCUMENTS

EP	0715618 B1	6/1996
JP	05-230044	9/1993
WO	WO 95/06030 A1	3/1995
WO	WO 98/56781	12/1998
WO	WO 99/51618	10/1999
WO	WO 99/67254	12/1999
WO	WO 99/67417 A2	12/1999
WO	WO 00/29390	5/2000
WO	WO 00/47551	8/2000
WO	WO 03/106461 A1	12/2003

## OTHER PUBLICATIONS

Seddon "Pseudopolymorph..." Crystal Growth & design v.4(6) p. 1087 (2004) (2 pages from internet).\*

Gyseghem et al. "Solid state chara . . ." AAOS Annual meeting abs. (2009).\*

Gao "Physical chemical . . ." AAPPS PharmSci. 3(1) p. 1-8 (2001).\*

Gyseghem "Solid state . . ." Eu. J.Pharm. Sci. 38 p. 489-497 (2009).\*

Vermeersch "Pseudopo . . ." CA140:47540 (2003).\*

International Search Report re: PCT/EP03/50176, dated May 16, 2003.

Giron D., et al., "Thermal analysis and calorimetric methods in the characterization of polymorphs and solvates," *Thermochimica Acta*, Elsevier Science Publishers, Amsterdam, vol. 248, 1995, pp. 1-59.

Borka L., et al., "Crystal polymorphism of pharmaceuticals," *Acta Pharmaceutica Jugoslavica*, Savez Farmaceutskih Drustava Jugoslavije, Zagreb, Yu, vol. 40, 1990, pp. 71-94.

Ghosh a.K., et al., "Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino) sulfonamide isostere," *Bioorganic & Medical Chemistry Letters*, Oxford, GB, vol. 8, No. 6, Mar. 17, 1998, pp. 687-690.

Grunenberg A., et al., "Theoretical derivation and practical application of energy/temperature diagrams as an instrument in preformulation studies of polymorphic drug substances," *International Journal of Pharmaceutics* 129 (1996) 147-158.

Byrn, S. R., et al., "Solid-State Chemistry of Drugs", Second Edition, 1999, published by SSCI, Inc., pp. 12-13.

Seddon, K., *Crystal Growth & Design*, 4 (6), p. 1087 (2004).

Braga, D., et al. "Making Crystals from Crystals: A Green Route to Crystal Engineering and Polymorphism", *Chem. Commun.*, pp. 3635-3645 (2002).

Kirk-Othmer Encyclopedia of Chemical Technology, "Crystallization", vol. 8 (2002) pp. 95-147 (2002).

Vermeersch, H., et al. "Pseudopolymorphic Forms of a HIV Protease Inhibitor", Caplus No. 1006987 (2003).

"Defendants Lupin Limited's, Lupin Pharmaceuticals, Inc.'s, Mylan Pharmaceuticals Inc.'s and Mylan Inc.'s Joint Invalidity Contentions Pursuant to Local Patent Rule 3.6(b)", in the United States District Court District of New Jersey, Consolidated Civil Action No. 10-5954-WHW-MCA, Nov. 18, 2011 (Redacted), 178 pages.

"Hetero Drugs, Ltd.'s Certification of Non-Infringement and/or Invalidity of United States Patent Nos. 5,843,946, 6,037,157, 6,248,775, 6,335,460, 6,703,403, 7,470,506, and 7,700,645", Feb. 10, 2011 (Redacted), 73 pages.

"Lupin Ltd.'s Notification of Certification of U.S. Patent Nos. 6,037,157, 6,703,403, 7,470,506, and 7,700,645 Pursuant to § 505(j)(2)(B)(iv) of the Federal Food, Drug, and Cosmetic Act", Jun. 3, 2011 (Redacted), 96 pages.

"Teva Pharmaceuticals USA, Inc.'s and Teva Pharmaceutical Industries, Ltd.'s Invalidity Contentions Under Local Patent Rules 3.3 and 3.6", Nov. 18, 2011 (Redacted), 123 pages.

Ansel et al., "Pharmaceutical Dosage Forms and Drug Delivery Systems", Lippincott Williams & Wilkins, 7<sup>th</sup> ed., 1999, 297-304.

Bauer, "Ritonavir an Extraordinary Example of Conformational Polymorphism", vol. 18, *Pharmaceutical Res.*, 2001, 859-866.

Berstein, J., "Polymorphism in Molecular Crystals", Oxford University Press, pp. 4-8, 2002.

Brittain, H.G., "Polymorphism in Pharmaceutical Studies", Discovery Laboratories, Inc., 1999, pp. 205-208.

Byrn, S. et al., "Pharmaceutical Solids A Strategic Approach to Regulatory Considerations", *Pharmaceutical Res.*, vol. 12, No. 7, 1995, 945-954.

(Continued)

Primary Examiner — Celia Chang

(74) Attorney, Agent, or Firm — Woodcock Washburn LLP

(57) **ABSTRACT**

New pseudopolymorphic forms of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[(4-aminophenyl)sulfonyl] (isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate and processes for producing them are disclosed.

19 Claims, 18 Drawing Sheets